Fig. 1From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiencesTreatment results of Anti-IL5/IL5R therapy (reslizumab, mepolizumab or benralizumab) and anti-IgE therapy (omalizumab) in patients suffering from severe asthma. Oral corticosteroid (OCS) courses, antibiotic courses and all exacerbation events are presented as number during the last 12 months preceding biological therapy (blue columns) and the latest 12 months during biological therapy (orange columns). Patients with discontinued biological therapy were included in the analysesBack to article page